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Background: Self-monitoring of blood glucose (SMBG) has been recommended as a useful tool for improving
glycemic control, but is still an underutilized strategy and most diabetic patients are not aware of the actions that
must be taken in response to its results and do not adjust their treatment. The purpose of this study was to
evaluate the effectiveness and safety of an educational program for insulin self-adjustment based on SMBG in
poorly controlled patients with type 2 diabetes (T2DM).
Methods: A prospective, randomized, controlled 12-week intervention study was conducted on poorly controlled
insulin-requiring patients with T2DM. Twenty-three subjects were randomized to two educational programs: a 2-week
basic program with guidance about SMBG and types and techniques of insulin administration (group A, n = 12) and a
6-week program including the basic one and additional instructions about self-titration of insulin doses according to a
specific protocol (group B, n = 11). Patients were reviewed after 12 weeks and baseline to endpoint changes in glycated
hemoglobin (A1C), insulin doses, body weight and incidence of hypoglycemia were compared by paired and
independent Student t-tests.
Results: After 12 weeks, there was a significant reduction in A1C only in group B, but group comparison showed no
significant difference (p = 0.051). A higher percentage of subjects in group B achieved an A1C near the treatment target
(<7.5%) than in group A. Daily insulin dose increased non-significantly in the two groups and there was no significant
difference in the incidence of hypoglycemia or body weight changes between groups.
Conclusions: Training for self-titrating insulin doses combined with structured SMBG can safely improve glycemic
control in poorly controlled insulin-treated T2DM patients. This strategy may facilitate effective insulin therapy in routine
medical practice, compensating for any reluctance on the part of physicians to optimize insulin therapy and thus to
improve the achievement of recommended targets of diabetes care.
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Diabetes mellitus (DM) is one of the most common
chronic and costly conditions in the world, which is as-
sociated with serious comorbidities. Strict glycemic con-
trol has been shown to reduce the risk of micro- and
macrovascular complications [1-3]. However, despite im-
proved understanding of the disease and a variety of new
medications and technologies, many patients still fail to
achieve treatment targets and remain at risk of these
complications [2,4,5]. Particularly in Brazil, a recent
cross-sectional study including 5,692 outpatients with
type 2 diabetes (T2DM) showed that the rate of poor
glycemic control was 73% (90% among insulin-treated
subjects) [1].
As a typical chronic condition, DM requires continuous
care and successful management of this disease cannot be
achieved without deep patient involvement [2]. In this re-
spect, the effect of educational interventions on the acqui-
sition of self-care behaviors is particularly important for
improving glycemic control because self-management
provides a report of current treatment status, with imme-
diate therapeutic benefits and patient empowerment [6].
However, educational interventions that are brief, infre-
quent, or designed solely to increase patient knowledge
are unlikely to improve self-care or glycemic control as de-
sired [7].
Self-monitoring of blood glucose (SMBG) has been
recommended as a useful tool for improving glycemic
control and is considered an essential component in
treatment programs for patients with insulin-treated
DM, favoring dietary changes, physical activity and
pharmacological therapy, including titration of insulin
doses [1,4,8]. Nevertheless, despite the availability of the
method and of information, SMBG is still an underuti-
lized strategy and most diabetic patients are unaware of
the actions that must be taken in response to its results
and do not adjust their treatment [9-13].
Currently, most patients with T2DM requiring insulin
therapy have their doses titrated by their clinicians,
which is a time-consuming process. Evidence suggests
that this approach may not provide optimal glycemic
management for the patients [14]. The association be-
tween SMBG and glycemic control could be strength-
ened as healthcare professionals improve their ability to
teach patients self-management skills, to instill greater
awareness of this importance, to enhance their self-
confidence, and to motivate them to make behavioral
changes in response to readings [15]. Patients need to
understand why they are being asked to self-monitor,
what their glycemic targets are, and what attitudes they
should take based on the results of SMBG [4].
The aim of the present study was to evaluate the effect-
iveness and safety of an educational program for self-
adjustment of insulin doses associated with structuredSMBG for the improvement of glycemic control in poorly
controlled insulin-treated patients with T2DM at a sec-
ondary care unit in Brazil.
Methods
Objectives
The primary objective of this study was to compare
baseline to endpoint changes in glycemic control [(gly-
cated hemoglobin - A1C, mean blood glucose (MBG),
pre- and postprandial blood glucose (BG)] between two
groups submitted to different training programs. Sec-
ondary objectives included the assessment of changes in
daily, basal and prandial insulin doses, the number of
BG measurements per week and compliance with
SMBG, the incidence of hypoglycemia, and changes in
body weight.
Study design
This was a 12-week intervention, open-labeled, random-
ized and controlled study conducted from January 1st
through December 31st, 2013, at the Metropolitan Center
of Medical Specialties in Belo Horizonte, Brazil. The
study was approved by the local Institutional Ethics
Committee and all subjects gave written informed con-
sent to participate.
Insulin-treated subjects with T2DM and poor glycemic
control were included. Additional inclusion criteria were
diabetes duration of more than one year and signed in-
formed consent. Exclusion criteria were A1C ≤ 7.0% be-
fore entering the study, mental instability, or any
condition limiting the patients’ ability to follow the study
protocol. No systematic patient education was con-
ducted before the beginning of the study.
A total of 26 patients were enrolled and medical his-
tory, demographic and physical characteristics and DM
treatment practices were ascertained for each subject
during the run-in period. After applying the exclusion
criteria, 23 patients were electronically randomized to
receive one of two structured education packages as fol-
lows: group A (control) received a 2-week teaching pro-
gram to ensure insulin use and SMBG, and group B
(intervention) received a 6-week teaching program to
ensure insulin use, SMBG and self-adjustment of insulin
doses according to a specific protocol.
After the teaching program, baseline A1C was collected
from each subject and both groups started the 12-week
treatment period on their own. All subjects were instructed
to monitor five BG measurements on three consecutive
days per week and to record the values obtained in a diary
for BG data. During this period, group A had its treatment
adjusted only by the assistant physician at usual medical
appointments, while group B subjects were encouraged to
adjust basal and prandial insulin doses on their own and to
make bolus corrections with regular or ultra-rapid-acting
Table 1 Forced weekly insulin titration schedule for basal
and prandial insulin
Mean of self-monitored FPG values
from preceding 3 days
Adjust of nocturnal basal
insulin dosage (IU/day)
<90 mg/dL (5.0 mmol/L) −1
90-130 mg/dL (5.0-7.2 mmol/L) No adjustment
>130 mg/dL (7.2 mmol/L) +2
Mean of self-monitored pre-dinner values
from preceding 3 days
Adjust of diurnal basal
insulin dosage (IU/day)
<90 mg/dL (5.0 mmol/L) −2
90-130 mg/dL (5.0-7.2 mmol/L) No adjustment
>130 mg/dL (7.2 mmol/L) +2
Mean of self-monitored postprandial values
from preceding 3 days
Adjust of prandial insulin
dosage (IU/day)
<90 mg/dL (5.0 mmol/L) −1
90-180 mg/dL (5.0-10.0 mmol/L) No adjustment
>180 mg/dL (10.0 mmol/L) +1
FPG, fasting plasma glucose.
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men of oral agents remained fixed and stable throughout
the study. After 12 weeks, the patients were reviewed by
the investigator at a clinical visit and another A1C was
collected. The patients were weighed, final insulin doses
were recorded, and the BG log books were retained and
analyzed.
The educational program
The Educational Program was delivered by a doctor
(DDRS) in a structured course prepared for groups of 15
patients. Both groups underwent separately an initial
teaching program of 2 weeks with two 120-min meet-
ings, during which patients were instructed about the
types and use of insulin, glycemic targets, and use of the
BG device. Additionally, the patients were requested to
regularly perform five BG measurements (fasting, before
dinner and postprandial after breakfast, lunch and din-
ner) on 3 consecutive days per week and to record the
results in a log book. At these meetings, the doctor
assessed the correct use of the monitoring device and
the accuracy of patient self-monitoring. The patients ob-
tained printed material dealing with the principles of the
treatment of diabetes and the topics discussed during
each meeting. No diet instruction was given.
Group B subjects were additionally trained during four
extra meetings to adjust basal and bolus insulin doses on
their own according to a specific protocol. It was ex-
plained that SMBG plus their BG diaries would provide
them with information about their day-to-day glycemic
control, allowing them to make appropriate adjustments
to their insulin doses, which would eventually result in im-
proved diabetes control. In this group, insulin doses were
titrated to achieve a preprandial target glucose value of
90–130 mg/dL (5.0-7.2 mmol/L) and a postprandial glu-
cose value of 90–180 mg/dL (5.0-10.0 mmol/L). Add-
itional action was taken when glucose was above recently
recommended targets [5]. During each meeting, patterns
of SMBG and BG values were discussed in depth with the
patients so they could make changes in insulin doses. Pa-
tients participated actively in the learning process, includ-
ing group discussions and practical workshops.
The guidelines applied for changing both bolus and
basal insulin dosing according to SMBG are shown in
Table 1. Group B was instructed to initiate 2 units of
prandial insulin if postprandial BG was persistently
above 180 mg/dL (10.0 mmol/L) in the respective meal
after 3 days of evaluation. Additionally, this group re-
ceived instructions on how to make corrections of bo-
luses with regular or ultra-rapid-acting insulin based on
a prescription made by the investigator according to an
individually calculated sensitivity factor. Subjects were
told to test glucose whenever they experienced symp-
toms that might be related to hypoglycemia and weretaught how to behave in case of low BG levels, in
addition to recording the results in their glycemic diary.
Measurements and safety
A1C, body weight and daily, basal and bolus insulin doses
were measured at baseline and 12 weeks after the end of
the teaching program. The A1C was measured by high-
performance liquid chromatography (HPLC; HSi Variant
G7, Tosoh, Tokyo, Japan) with a reference range of 4.5–
6.9%. The study method for A1C analysis was certified by
the National Glycohemoglobin Standardization Program
and showed an interassay between-batch coefficient of
variation of 5.4% and 11.0% at mean A1C levels of 4.9 to
5.8% and 10.1 to 11.8%, respectively. Renal function was
assessed by calculating the estimated glomerular filtration
rate using the Cockcroft-Gault equation.
Glucose monitors and 200 BG testing strips were pro-
vided for subjects’ home BG monitoring during the 12-
week treatment period. A glucose meter (Accu-Chek
Active®, Roche Diagnostics, Brazil) was used as a stand-
ard device throughout the study and reported whole
blood results. The data and calibration of the BG me-
ters were verified during meeting 1 and reassessed dur-
ing additional meetings if necessary.
After the 12-week treatment period, average values of
pre- and postprandial BG and MBG were calculated for
each subject in both groups. Frequencies of BG tests per
week and of hypoglycemia were assessed by reviewing the
patients’ log books. Hypoglycemia was defined as a docu-
mented BG level of less than 70 mg/dL (3.9 mmol/L) with
or without symptoms and severe hypoglycemia was de-
fined as a hypoglycemic episode requiring assistance from
another person and treatment by intravenous glucose or
glucagon injection. Compliance with SMBG was calculated
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tient in relation to expected measures (200 per subject)
after 12 weeks.
Statistical analysis
Patients were included in the analysis if they had com-
pleted the entire protocol after assessment of exclusion
criteria. Parametric tests were used as variables were
found to follow a normal distribution. The paired Stu-
dent t-test was used to analyze the differences from
baseline to the endpoint in the same group. The inde-
pendent Student t-test was used for comparison of base-
line characteristics and of changes from baseline in A1C,
MBG, pre- and postprandial BG, insulin doses, body
weight and hypoglycemic events between groups after
the 12-week treatment period. The percentage of sub-
jects achieving glycemic targets was calculated using
Fisher’s exact test. Data are reported as the mean ±
standard deviation (s.d.) unless otherwise stated, and a p
value of less than 0.05 was used to indicate a significant













Figure 1 Study overview and design.(SPSS) for Windows, version 20.0 (2012), was used for
data analysis.Results
Subjects
Twenty-six subjects were screened and 23 were found to
be eligible to be enrolled in the teaching program. Twelve
patients were randomized to group A and 11 patients to
group B. Most subjects (n = 22, 95.6%) completed the
study. One subject from group B was lost to follow-up for
unknown reasons and was excluded from analysis. The
final population included 12 subjects in group A and 10
subjects in group B (Figure 1). Compliance with the edu-
cational meetings was 100%.
Baseline demographic and clinical characteristics are
shown in Table 2. There were no significant differences be-
tween groups regarding baseline parameters. Five patients
(23%) used conventional insulin therapy, i.e., two or fewer
insulin injections per day, and 17 patients (77%) used mul-












Table 2 Baseline demographic and clinical characteristics







Subjects (n) 12 10
Age (years) 55.4 ± 12.6 60.0 ± 11.3 0.385
Sex (male: female)*** 3:9 4:6 0.652
Duration of Diabetes (years) 16.4 ± 7.9 17.6 ± 9.0 0.745
Body weight (Kg) 78.1 ± 17.4 71.8 ± 20.7 0.444
BMI (Kg/m2) 30.2 ± 6.0 28.4 ± 6.4 0.552
A1C (%) 9.6 ± 1.6 9.0 ± 0.8 0.309
eGFR (ml/min) 75.2 ± 29.0 55.5 ± 30.5 0.137
Insulin treatment duration (years) 11.2 ± 7.4 8.4 ± 6.0 0.344
Entry insulin dose (IU/day) 66.1 ± 19.0 71.7 ± 47.2 0.709
Entry insulin dose (IU/Kg/day) 0.9 ± 0.3 1.0 ± 0.4 0.641
Basal insulin dose (IU/day) 54.3 ± 13.3 56.8 ± 32.3 0.811
Bolus insulin dose (IU/day) 11.8 ± 12.5 14.9 ± 18.5 0.640
BMI, body mass index; A1C, glycated hemoglobin A1C; eGFR, estimated
Glomerular Filtration Rate.
*Results are presented as mean ± s.d. (except for Sex, male: female ratio).
**P-values of Independent Student’s t-test, level of significance of 0.05.
***P-values of Exact Fisher’s Test, level of significance of 0.05.
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rapid-acting insulin.Glycated hemoglobin
After 12 weeks, a significant reduction in A1C was only
observed in group B, but comparison between groups
revealed no significant difference (Tables 3 and 4). After
the same period, one of patient in group B had reached
the guideline target of A1C < 7.0%, 50% had A1C ≤ 7.5%,
and only one (10%) had A1C > 9.0%. In group A, no pa-
tient obtained A1C < 7.0%, only one had A1C ≤ 7.5%,
and 58.3% had A1C > 9.0% (p < 0.005). A higher percent-
age of subjects in group B achieved an A1C near the
treatment target (<7.5%) than in group A (50.0 vs. 8.3%,
p < 0.029).Table 3 Comparative results before and after intervention ins
Group A (n = 12)
Pre Post
A1C (%) 9.6 ± 1.6 9.0 ± 1.1
Body weight (Kg) 78.1 ± 17.4 78.1 ± 17.8
Daily insulin dose (IU/day) 66.1 ± 19.0 70.9 ± 25.5
Daily insulin dose (IU/Kg/day) 0.9 ± 0.3 0.9 ± 0.3
Basal insulin dose (IU/day) 54.3 ± 13.3 55.3 ± 16.6
Bolus insulin dose (IU/day) 11.8 ± 12.5 15.6 ± 13.6
A1C, glycated hemoglobin A1C.
*Results are presented as mean ± s.d.
**P-values of Paired Student’s t-test, level of significance of 0.05.Blood glucose measures
After the 12-week treatment period, there was no signifi-
cant difference in MBG or pre- and postprandial BG be-
tween groups (Table 4). The average number of BG
measurements was 11.9 ± 3.4 tests per week in group A
and 18.3 ± 5.5 tests per week in group B. The larger
number of weekly BG measurements in group B was sta-
tistically significant (p < 0.003). Compliance with SMBG
(performed/expected readings) after the 12 weeks of
treatment was 0.8 ± 0.2 in group A and 1.2 ± 0.4 in group
B. The higher compliance in group B was also statisti-
cally significant (p < 0.004) (Table 5).
Insulin doses
Daily, basal and bolus insulin doses increased non-
significantly in the two groups (Table 3) and the baseline
to endpoint increase in insulin doses was not signifi-
cantly different between groups (Table 5).
Safety
The adverse events are shown in Table 5. There were no
severe hypoglycemic episodes in this study and the over-
all frequency of minor hypoglycemia was not signifi-
cantly different between groups. There was no gain in
body weight from baseline to endpoint in either group
and no significant differences were observed between
groups in terms of body weight change after 12 weeks.
Discussion
The increasing prevalence of T2DM, together with the
world’s ageing population, places an increasing burden
on healthcare systems, particularly healthcare profes-
sionals [14,16]. Thus, diabetes self-management educa-
tional programs have been considered by some authors
as an essential strategy for improving the health behav-
iors of diabetic adults [1,14,17].
The success of long-term management of insulin-
requiring patients with T2DM is the result of a complex
interaction of different factors, including the mode of in-
sulin and diet therapy, individual motivation and self-careide the groups*
Group B (n = 10)
P value** Pre Post P value**
0.131 9.0 ± 0.8 8.0 ± 1.2 0.006
1.00 71.8 ± 20.7 70.8 ± 21.5 0.378
0.158 71.7 ± 47.2 79.0 ± 52.0 0.177
0.188 1.0 ± 0.4 1.1 ± 0.5 0.109
0.491 56.8 ± 32.3 61.2 ± 34.4 0.306
0.078 14.9 ± 18.5 17.8 ± 19.0 0.079
Table 4 Comparative results of glycemic control between groups after 12 weeks*
Group A (Control) Group B (Intervention) P value**
Subjects (n) 12 10
A1C (%) 9.0 ± 1.1 8.0 ± 1.2 0.051
MBG mg/dL (mmol/L) 184.1 ± 36.2 (10.2 ± 2.0) 162.3 ± 30.2 (9.0 ± 1.7) 0.145
Mean FPG mg/dL (mmol/L) 170.5 ± 50.2 (10.2 ± 2.0) 142.2 ± 37.2 (7.9 ± 2.1) 0.156
Mean Post Breakfast BG mg/dL (mmol/L) 194.8 ± 51.2 (10.8 ± 2.8) 172.2 ± 36.9 (9.6 ± 2.1 0.259
Mean Post-lunch mg/dL (mmol/L) 171.8 ± 36.2 (9.54 ± 2.0) 165.7 ± 27.9 (9.2 ± 1.6) 0.677
Mean before dinner BG mg/dL (mmol/L) 179.9 ± 38.4 (10.0 ± 2.1) 160.9 ± 39.4 (8.9 ± 2.2) 0.267
Mean Bed-time BG mg/dL (mmol/L) 209.9 ± 50.6 (11.7 ± 2.8) 179.3 ± 30.6 (9.9 ± 1.7) 0.110
A1C, glycated hemoglobin A1C; MBG, mean blood glucose; FPG, fasting plasma glucose; BG, blood glucose.
*Results are presented as mean ± s.d.
**P-values of Independent Student’s t-test, level of significance of 0.05.
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the treatment of their illness [16]. It has been suggested
that different or better implementation of existing ap-
proaches is needed to help patients understand and
achieve glycemic targets in order to improve glycemic
control and to prevent or delay the complications of DM
[11].
Treatment guidelines by global organizations recom-
mend insulin intensification to achieve A1C targets as
T2DM progresses, but fewer patients are being pro-
gressed than would be indicated based on their disease
status [18,19]. Evidence suggests that in conventional
regimens guided by physicians subjects remain on low
doses of insulin and are seldom titrated sufficiently to








Subjects (n) 12 10
SMBG (tests/week) 11.9 ± 3.4 18.3 ± 5.5 0.003
Compliance with
SMBG
0.8 ± 0.2 1.2 ± 0.4 0.004
After insulin dose
(IU/day)
70.9 ± 25.5 79.0 ± 52.0 0.639
After insulin dose
(IU/Kg/day)
0.9 ± 0.3 1.1 ± 0.5 0.427
Basal insulin dose
(IU/day)
55.3 ± 16.6 61.2 ± 34.4 0.606
Bolus insulin dose
(IU/day)
15.6 ± 13.6 17.8 ± 19.0 0.754
Hypoglycemia
(episodes/period)
8.2 ± 9.1 12.8 ± 13.0 0.338
Body weight (Kg) 78.1 ± 17.8 70.8 ± 21.5 0.393
BMI (Kg/m2) 30.2 ± 6.2 28.0 ± 6.6 0.435
SMBG, self-monitoring blood glucose; BMI, body mass index.
*Results are presented as mean ± s.d.
**P-values of Independent Student’s t-test, level of significance of 0.05.titration regimen that could be successfully undertaken
by the patients themselves would be beneficial.
We anticipated that if patients were able and willing to
undergo a program of self-adjustment of insulin doses
associated with structured SMBG, their metabolic con-
trol would improve. The aim of the present study was to
test the effectiveness, practicability and safety of an out-
patient program that could help patients with T2DM to
make safe and effective intensive insulin therapy self-
adjustments.
Some randomized controlled trials examining different
self-titration techniques, most of them with basal or pre-
mixed insulin analogues, have found that self-adjustment
of insulin is effective in helping patients with T2DM safely
meet their treatment goals [9,13,20-25]. However, few
studies are available that specifically consider patients
already on insulin therapy and using NPH insulin. In a re-
cent cross-sectional study carried out to investigate the
hypothesis that self-titration of insulin would improve
metabolic control, Beluchin et al. found that two thirds of
patients who had undergone training for self-management
practiced it, but there were no significant differences re-
garding A1C between patients who did or did not perform
self-adjustment [26].
In the present study, patients who received training in
self-titrating insulin doses according to a specific proto-
col achieved a significant reduction in A1C levels from
9.0 ± 0.8 to 8.0 ± 1.2% (p < 0.006) after a period of
12 weeks, while this effect was not detected in the con-
trol group (A1C: 9.6 ± 1.6 to 9.0% ± 1.1%, p = 0.131). This
improvement in A1C was achieved with a nonsignificant
incidence of hypoglycemia or change in body weight,
which could be concerns regarding the safety of a self-
titration insulin regimen.
However, when the two groups were compared regard-
ing baseline to endpoint A1C, there was no statistically
significant difference (p = 0.051), although this border-
line p value could indicate a strong trend in favor of
self-adjustment and a result of clinical significance. This
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patients of the intervention group and in 50% of the
control patients and that a larger number of individuals
in group B achieved an A1C near the treatment target
(<7.5%), with the difference being significant (50 vs.
8.3%, p < 0.029). This finding could be considered an im-
portant short-term therapeutic response.
Basal, bolus and total insulin doses did not differ be-
tween groups after 12 weeks. A possible explanation for
the better results in the intervention group could be the
fact that these patients were instructed on how to per-
form insulin bolus corrections for high BG measures
based on an individual sensitivity factor. These boluses
were not accounted for in the final insulin doses and
were difficult to quantify during the 12-week treatment
period, but all group B patients reported to have used
this technique. Similar findings have been reported by
Pieber et al., who described significant improvement in
A1C without a change of insulin doses after an out-
patient education program designed to intensify insulin
therapy [27].
Few publications have described the relationship be-
tween SMBG and glycemic control beyond the fre-
quency of testing to determine whether patients clearly
understand their glycemic targets and how they respond
to the information obtained from monitoring [10,15,28].
SMBG is an essential part of management for patients
who properly self-adjust their insulin doses and patients
need to know and understand their BG goals and what
steps to take in response to a high or low reading, such
as diet changes, exercise, and/or medication [4,29].
In the present study, the number of BG tests per week
and the compliance with the expected SMBG rate were
significantly higher in the intervention group. Despite
the small sample size, these results may have contributed
to the achievement of a significant reduction of A1C in
group B. Some authors have proposed that educational
programs focusing on enhanced SMBG seem to be a
stimulus for behavioral change on the part of the pa-
tients, empowering and giving them the confidence to
become more involved in their treatment and resulting
in improved glycemic control. This also applies to those
who do not self-adjust insulin doses, with the informa-
tion provided by the BG being used to promote lifestyle
changes [14,15,30].
Thus, these findings could suggest that it is possible to
use a titration regimen applied by the subjects them-
selves to their treatment management with positive re-
sults in glycemic control, but some limitations should be
highlighted. The main limitation is the small sample size
given our limited availability of BG testing strips to per-
form the protocol, which may have impacted the results
and have conferred a strength of 70% to this study. A
larger sample could increase the power of the study anddemonstrate a significant difference between the strategy
of self-titration and conventional treatment, favoring the
diffusion of the former [31]. Another limitation was the
selection of an outpatient population treated in a spe-
cialized medical center, so that whether or not or to
what extent these results are applicable to other patient
populations is unknown. A possible contamination effect
should be pointed out in view of the infeasibility of
blinding the participants, with the awareness of the
group being included in a study possibly contributing to
the effect of such study. As done in most studies, we
have compared a more intensive intervention to basic
care and education, since it is generally considered un-
ethical to randomize a group to receive no education,
which could have minimized the measured effects of the
intervention [32].
Currently, most insulin-requiring patients with T2DM
have their treatment titrated by their clinicians at inter-
vals of three months, which can be a time-consuming
and wearing process that may not provide optimal gly-
cemic management for the patients [14]. The present
study provides treatment optimization with insulin titra-
tion performed by elderly and middle-aged diabetic pa-
tients with longstanding disease, allowing them to safely
and effectively participate in the management of their
treatment. This approach has the potential to signifi-
cantly improve their glycemic control and to reduce the
burden of care for healthcare professionals. Empowering
patients to take up a more active role in their therapy
through self-titration of insulin dosing may, in some
cases, be more effective than physician-directed titration
in achieving glycemic control, and may also take some
strain off overstretched primary care physicians through
reduced patient visits [14].
The present findings may have important implications
for educational program planning in DM treatment. The
feasibility of this kind of teaching program for this pa-
tient profile is evidenced by the high rate of compliance
in the intervention group versus the control group, the
practicality of the treatment algorithm, the correction of
hyperglycemia, and the lack of increase in the frequency
of hypoglycemic reactions. The program also involves
aspects of treatment that, if strengthened, would prob-
ably further improve metabolic control and offset any re-
luctance on the part of physicians to progress insulin
therapy at the time of regular appointments.Conclusions
The present pilot study suggests that a relatively inex-
pensive educational program with insulin self-titration
interventions based on structured SMBG significantly
reduces A1C during a follow-up of 12 weeks and shows
a trend towards greater effectiveness in improving
Silva and Bosco Diabetology & Metabolic Syndrome 2015, 7:2 Page 8 of 9
http://www.dmsjournal.com/content/7/1/2glycemic control than conventional treatment, with no
increase in incidence of hypoglycemia or body weight
gain. Larger randomized, controlled studies are needed
to definitively assess the effectiveness of diabetes educa-
tion programs focusing on insulin self-adjustment for
patients with T2DM.Abbreviations
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